Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zspeplib Announces $14 Million Round for Novel Peptide Drug Discovery

publication date: Jul 31, 2019

Hunan Zhongsheng Whole Peptide Biochemical, also known as Zspeplib, recently completed a $14 million Series A financing led by Tasly Group. The funds will be used to build a hexapeptide library, optimize the company's peptide-based new drug screening platform and develop new drugs. Zspeplib uses peptide information compression technology (PICT) to build a complete library of peptides with independent IP. Its technology reduces the cost of building a peptide library and can improve the efficiency of building a database by 6000 times, the company said. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital